logo
#

Latest news with #North Carolina

Huntington Bancshares lifts 2025 interest income forecast as loan growth shines
Huntington Bancshares lifts 2025 interest income forecast as loan growth shines

Yahoo

time21 hours ago

  • Business
  • Yahoo

Huntington Bancshares lifts 2025 interest income forecast as loan growth shines

(Reuters) -Regional lender Huntington Bancshares on Friday raised its annual interest income forecast, betting on robust loan growth and lower deposit costs. The Columbus, Ohio-based Huntington has delivered strong growth in its core businesses and expanded to North and South Carolinas and Texas in recent years, despite high interest rates squeezing loan demand for regional banks. Rate cuts by the U.S. Federal Reserve last year have also allowed banks to reduce deposit costs. The bank now expects net interest income (NII) - the difference between what it earns on loans and pays out on deposits - to grow between 8% and 9% in 2025, compared with its prior forecast of 5% and 7% rise. Annual loan growth is expected between 6% and 8%, higher than its prior forecast of 5% to 7% rise. NII jumped 12% to $1.47 billion in the second quarter, putting the bank on track for a record full-year interest income. Average total loans and leases grew $9.8 billion from the year-ago quarter. Huntington's profit per share rose to 34 cents in the quarter ending June 30, from 30 cents a year earlier. On Monday, Huntington struck a $1.9 billion deal for rival Veritex, furthering its Texas push. BOND PORTFOLIO REJIG Months after a similar move, Huntington rejigged a portion of its securities portfolio to boost profits, as banks increasingly dump lower-yielding securities. Huntington sold $900 million of corporate bonds in the quarter and reinvested proceeds into higher-yielding securities, resulting in a pre-tax loss of $58 million. The rejig is expected to boost revenue and interest margin in the second half of the year and into 2026, with Huntington picking up about 340 basis points of yield on the trade. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

D.C. United's winless run hits seven: ‘It's tough for the lads'
D.C. United's winless run hits seven: ‘It's tough for the lads'

Washington Post

time2 days ago

  • Sport
  • Washington Post

D.C. United's winless run hits seven: ‘It's tough for the lads'

Mired in a prolonged rut and shaken by a coaching change, D.C. United is not having the best of summers. Remove three starters before Wednesday night's match against Charlotte FC, and United faced a dire outlook at Bank of America Stadium. The adrift MLS club remained on even terms until almost halftime, but a goal just before intermission and another just after it led to a 2-1 setback that extended United's winless streak to six in league play and seven overall.

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Yahoo

time3 days ago

  • Business
  • Yahoo

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the treatment of concussion. This agreement is expected to ensure Good Manufacturing Practice (GMP)-compliant drug product supply ahead of the planned Phase IIb clinical trials which the Company expects to start next year. The collaboration marks an important milestone for Oragenics as it secures domestic production capabilities to support its upcoming clinical and regulatory efforts. 'We are excited to partner with Sterling's facility in Cary, North Carolina, to support the production of ONP-002,' said Janet Huffman, Chief Executive Officer of Oragenics. 'This partnership is a critical milestone in our path forward for Phase IIb clinical trials. This partnership reinforces our commitment to quality, efficiency, and U.S.-based innovation and we believe this step will help streamline our clinical development strategy.' Sterling will produce ONP-002 under strict cGMP conditions for use in Oragenics' planned Phase IIb trials, a proof-of-concept study which will evaluate early efficacy of ONP-002 in patients with mild traumatic brain injury (mTBI). Chad Telgenhof, Chief Commercial Officer at Sterling Pharma Solutions, said: 'We are pleased to be partnering with Oragenics for the GMP production of its lead molecule for clinical trials. Our scientific expertise in CNS therapies and our ability to meet critical timelines will support the continued path to market for this transformative drug candidate.' This U.S.-based manufacturing agreement builds upon Oragenics' broader strategy to develop scalable, accessible, and fast-acting treatments for neurological trauma, beginning with concussion, a condition that currently has no FDA-approved pharmacological therapies. About Oragenics, Inc. Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders. Its lead candidate, ONP-002, is being developed for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion. The Company's intranasal delivery technology is designed to deliver fast, targeted, and non-invasive therapy to the brain. For more information, please visit About Sterling Pharma SolutionsSterling Pharma Solutions is a global contract development and manufacturing organization (CDMO) with more than 50 years' experience in providing small molecule API development and manufacturing services to the pharmaceutical industry, specializing in handling challenging chemistries. Sterling manages the most complex API challenges from proof-of-concept to commercial manufacture, as well as antibody-drug conjugate (ADC) research and development bioconjugation services. Sterling has six facilities employing more than 1,350 people: its HQ in Dudley, Cramlington, UK and a site in Newcastle upon Tyne, UK; a European presence in Ringaskiddy, Co. Cork, Ireland; a dedicated bioconjugation and ADCs facility in Deeside, North Wales, UK; and two sites in the US, in Cary, North Carolina and Germantown, Wisconsin. Find out more at Forward-Looking Statements This communication contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words 'believe,' 'expect,' 'anticipate,' 'intend,' 'estimate,' 'project' and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law. Oragenics, HuffmanChief Executive Officer813-286-7900jhuffman@ Investor Contact:Rich CockrellCG Capital866.889.1972ogen@

American Airlines will introduce a quick-serve lounge in Charlotte
American Airlines will introduce a quick-serve lounge in Charlotte

Travel Weekly

time4 days ago

  • Business
  • Travel Weekly

American Airlines will introduce a quick-serve lounge in Charlotte

American Airlines will introduce a quick-service lounge, Provisions by Admirals Club, with the first opening planned for Charlotte Douglas International Airport late this summer. Provisions by Admirals Club will be geared toward travelers in a hurry. The space, to be located in the airport's Concourse A, will offer a variety of sandwiches, salads, snacks and fruit. The space will be laid out with high-top standing tables and minimal furniture to facilitate quick visits and accommodate high-volume traffic. American said Provisions staff will assist customers just like they do in the Admirals Club. The quick-serve lounge will be open to flyers under the same rules as standard Admirals Clubs. American's plan to open the new quick-stop lounge is the latest in a string of customer-facing initiatives this year. The quick-serve trend American Express also announced Tuesday that it would introduce a quick-stop lounge, called Sidecar by the Centurion Lounge. The concept will debut in Las Vegas next year. United was the first U.S. carrier to open lounges for flyers on the go. It debuted United Club Fly in Denver in 2022 and opened a second Club Fly at Houston Bush Intercontinental early this year.

Four-star offensive lineman commits to Tennessee over South Carolina, Ohio State
Four-star offensive lineman commits to Tennessee over South Carolina, Ohio State

Yahoo

time5 days ago

  • Sport
  • Yahoo

Four-star offensive lineman commits to Tennessee over South Carolina, Ohio State

Tennessee added a commitment to its 2026 football recruiting class. Four-star offensive lineman JB Shabazz committed to the Vols over South Carolina and Ohio State on Friday. The 6-foot-6, 315-pound prospect is from East Forsyth High School in Kernersville, North Carolina. 247Sports ranks Shabazz as the No. 29 offensive tackle in the class and the No. 16 player in North Carolina. Advertisement Tennessee offered him a scholarship on Feb. 11. Shabazz officially visited Tennessee on June 13. The Vols have 21 commitments in their 2026 football recruiting class. Tennessee's other 20 commitments include quarterback Faizon Brandon, wide receiver Tyreek King, tight end Carson Sneed, offensive lineman Gabriel Osenda, linebacker Braylon Outlaw, defensive lineman CJ Edwards, defensive lineman Zach Groves, safety KJ McClain, safety Luke Thompson, defensive end Kedric Golston II, offensive lineman Edward Baker, wide receiver Zaydyn Anderson, quarterback Legend Bey, defensive lineman Dereon Albert, linebacker TJ White, cornerback Jamyan Theodore, defensive lineman Darryl Rivers, wide receiver Javonte Smith, linebacker Brayden Rouse and safety Jowell Combay. Follow Vols Wire on Facebook and X (formerly Twitter). This article originally appeared on Vols Wire: Four-star offensive lineman commits to Tennessee football

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store